SRRK
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Scholar Rock resubmitted BLA to the FDA for apitegromab in spinal muscular atrophyMar 31, 2026
- FDA issues Complete Response Letter (CRL) for Apitegromab as treatment for spinal muscular atrophy (SMA) due to observations at Catalent Indiana LLC fill-finish facilitySep 23, 2025
- Scholar Rock reports positive Phase 2 EMBRAZE trial results showing significant lean mass preservation with Apitegromab during Tirzepatide-induced weight lossJun 18, 2025